Cambridge University Hospitals NHS Foundation Trust
Cambridge University Hospitals NHS Foundation Trust
Cambridge, United Kingdom34 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE) | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hereditary Complement Deficiency Diseases, Hypersensitivity, Immediate, Primary Immunodeficiency Diseases, Skin and Connective Tissue Diseases, angioedema, cardiovascular disorder, hereditary angioedema, hereditary disease, immune system disorder, inborn error of immunity, skin disorder, skin vascular disease, urticaria, vascular disorder | Active, not recruiting | Phase 3 | 2026-10-08 | NCT06634420 | |
| Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension | cardiovascular disorder, hypertensive disorder, vascular disorder | Active, not recruiting | Phase 3 | 2026-09-29 | NCT05968430 | |
| Nipocalimab in Moderate to Severe Sjogren's Disease | Sjogren syndrome, Skin and Connective Tissue Diseases, Stomatognathic Diseases, Xerostomia, arthritic joint disease, arthropathy, autoimmune disease, connective tissue disorder, dry eye syndrome, eye disorder, immune system disorder, lacrimal apparatus disorder, mouth disorder, musculoskeletal system disorder, rheumatic disorder, rheumatoid arthritis, salivary gland disorder | Active, not recruiting | Phase 3 | 2026-09-25 | NCT06741969 | |
| A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | gastroesophageal junction adenocarcinoma | Recruiting | Phase 3 | 2026-09-14 | NCT07043400 | |
| Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis | Digestive System Diseases, colitis, colonic disorder, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder, ulcerative colitis | Active, not recruiting | Phase 2 | 2026-09-11 | NCT06029972 | |
| Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Recruiting | Phase 1 / Phase 2 | 2026-09-08 | NCT07002320 | |
| KORTUC Phase II - Intra-tumoural Radiation Sensitizer in Patients With Locally Advanced/Recurrent Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2026-09-02 | NCT03946202 | |
| A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN) | Frontotemporal Lobar Degeneration, Neurobehavioral Manifestations, Neurologic Manifestations, Nutritional and Metabolic Diseases, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, TDP-43 proteinopathy, aphasia, brain disorder, central nervous system disorder, cognitive disorder, communication disorder, dementia, frontotemporal dementia, language disorder, metabolic disease, nervous system disorder, neurodegenerative disease, primary progressive aphasia, proteostasis deficiencies, psychiatric disorder, speech disorder | Recruiting | Phase 1 / Phase 2 | 2026-08-13 | NCT06064890 | |
| Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26) | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine disorder | Active, not recruiting | Phase 3 | 2026-07-29 | NCT06486441 | |
| A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | Advanced Solid Tumors; Metastatic Solid Tumors; Solid Tumors | Recruiting | Phase 1 | 2026-07-23 | NCT05836324 | |
| Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Neoplasms by Site, Neoplasms, Multiple Primary, Thoracic Neoplasms, autosomal dominant Parkinson disease 4, bronchial neoplasm, bronchogenic carcinoma, endocrine system disorder, hereditary disease, hereditary neoplastic syndrome, lethal congenital contracture syndrome 2, lung disorder, lung neoplasm, malignant endocrine neoplasm, multiple endocrine neoplasia, multiple endocrine neoplasia type 2A, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm, type 1 diabetes mellitus 12 | Recruiting | Phase 1 | 2026-07-22 | NCT05142189 | |
| A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, carcinoma, epithelial neoplasm, neoplasm, transitional cell carcinoma, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder, urothelial carcinoma | Recruiting | Phase 2 | 2026-07-22 | NCT04879329 | |
| Safety and Clinical Activity of QEL-001 in A2-mismatch Liver Transplant Patients | Digestive System Diseases, Hepatic Insufficiency, liver disorder, liver failure | Active, not recruiting | Phase 1 / Phase 2 | 2026-07-02 | NCT05234190 | |
| A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP) | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, anemia, familial hemolytic anemia, hematologic disorder, hemolytic anemia, hereditary disease, inherited hemoglobinopathy, sickle cell disease | Active, not recruiting | Phase 2 / Phase 3 | 2026-06-23 | NCT05031780 | |
| Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo) | Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, leiomyosarcoma, myomatous neoplasm, neoplasm, sarcoma | Active, not recruiting | Phase 3 | 2026-06-18 | NCT06088290 | |
| A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease | Bronchiolitis Obliterans, bronchial disorder, bronchiolitis, bronchiolitis obliterans syndrome, bronchitis, cryptogenic organizing pneumonia, graft versus host disease, immune system disorder, lung disorder, obstructive lung disease, respiratory system disorder | Active, not recruiting | Phase 2 | 2026-05-22 | NCT06388564 | |
| A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Skin and Connective Tissue Diseases, Urogenital Diseases, anti-neutrophil cytoplasmic antibody-associated vasculitis, autoimmune disease, cardiovascular disorder, connective tissue disorder, glomerulonephritis, immune system disorder, kidney disorder, lupus nephritis, muscle tissue disorder, musculoskeletal system disorder, myositis disease, necrotizing vasculitis, nephritis, nervous system disorder, neuromuscular disease, skin disorder, skin vascular disease, systemic lupus erythematosus, systemic sclerosis, urinary system disorder, vascular disorder, vasculitis | Recruiting | Phase 1 | 2026-05-22 | NCT06308978 | |
| DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2) | Noonan syndrome 5, low grade glioma | Active, not recruiting | Phase 3 | 2026-05-14 | NCT05566795 | |
| IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Thyroid Cancer, Papillary, adenocarcinoma, carcinoma, endocrine system disorder, epithelial neoplasm, malignant endocrine neoplasm, neoplasm, papillary adenocarcinoma, thyroid Hurthle cell carcinoma, thyroid gland disorder, thyroid gland follicular carcinoma, thyroid tumor | Active, not recruiting | Phase 2 / Phase 3 | 2026-05-07 | NCT01398085 | |
| Explore the Efficacy and Mechanism of Action of Tezepelumab in Eosinophilic Granulomatosis With Polyangiitis | Granuloma, Hemic and Lymphatic Diseases, Skin and Connective Tissue Diseases, anti-neutrophil cytoplasmic antibody-associated vasculitis, autoimmune disease, cardiovascular disorder, eosinophilic granulomatosis with polyangiitis, immune system disorder, lymphatic system disorder, lymphoproliferative syndrome, necrotizing vasculitis, skin disorder, skin vascular disease, vascular disorder, vasculitis | Active, not recruiting | Phase 2 | 2026-04-29 | NCT06230354 | |
| Effect of infLuenza vaccInation After Myocardial INfArction on Cardiac inflammaTory responsE | Infections, RNA Virus Infections, acute myocardial infarction, cardiovascular disorder, influenza, respiratory system disorder, respiratory tract infectious disorder, viral infectious disease | Recruiting | Phase 4 | 2026-04-07 | NCT06336317 | |
| A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL | B-cell chronic lymphocytic leukemia, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 3 | 2026-03-09 | NCT03336333 | |
| Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial | Nutritional and Metabolic Diseases, TDP-43 proteinopathy, amyotrophic lateral sclerosis, central nervous system disorder, metabolic disease, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, proteostasis deficiencies, spinal cord disorder | Recruiting | Phase 2 / Phase 3 | 2026-03-04 | NCT04302870 | |
| Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression | Adnexal Diseases, Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, breast disorder, breast neoplasm, bronchial neoplasm, bronchogenic carcinoma, carcinoma, digestive system disorder, digestive system neoplasm, endocrine system disorder, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, gastric neoplasm, gonadal disorder, head and neck cancer, head and neck squamous cell carcinoma, lung disorder, lung neoplasm, malignant endocrine neoplasm, neoplasm, non-small cell lung carcinoma, ovarian cancer, ovarian disorder, respiratory system disorder, respiratory tract neoplasm, skin disorder, squamous cell carcinoma, stomach disorder, triple-negative breast carcinoma, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder | Active, not recruiting | Phase 1 / Phase 2 | 2025-11-17 | NCT04180371 | |
| Comparing UroLift Experience Against Rezūm | Genital Diseases, Male Urogenital Diseases, Urogenital Diseases, benign prostatic hyperplasia, male reproductive system disorder, prostate disorder | Active, not recruiting | Not applicable | 2025-10-14 | NCT04338776 |